| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The peroxisome proliferator-activated receptor (PPAR) is a member of the steroid hormone receptor superfamily and is activated by a variety of fibrate hypolipidaemic drugs and non-genotoxic rodent hepatocarcinogens that are collectively termed peroxisome proliferators. A key marker of peroxisome proliferator action is the peroxisomal enzyme acyl CoA oxidase, which is elevated about tenfold in the livers of treated rodents. We have previously shown that a peroxisome proliferator response element (PPRE) is located 570 bp upstream of the rat peroxisomal acyl CoA oxidase gene and that PPAR binds to it. We show here that the retinoid X receptor (RXR) is required for PPAR to bind to the PPRE, and that the RXR ligand, 9-cis retinoic acid, enhances PPAR action. Retinoids may therefore modulate the action of peroxisome proliferators and PPAR may interfere with retinoid action, perhaps providing one mechanism to explain the toxicity of peroxisome proliferators. We have also shown that a variety of hypolipidaemic drugs and fatty acids can activate PPAR. This supports the suggestion that the physiological role of PPAR is to regulate fatty acid homeostasis, and provides further evidence that PPAR is the target of the fibrate class of hypolipidaemic drugs. Finally, we have demonstrated that a metabolically stabilized fatty acid is a potent PPAR activator, suggesting that fatty acids, or their acyl CoA derivatives, may be the natural ligands of PPAR.
This article has been cited by other articles:
|
|
 |
|
  L. M. Alleva, C. Cai, and I. A. Clark Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza Evid. Based Complement. Altern. Med., September 24, 2009; (2009) nep152v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Gocke, R. Z. Hussain, Y. Yang, H. Peng, J. Weiner, L.-H. Ben, P. D. Drew, O. Stuve, A. E. Lovett-Racke, and M. K. Racke Transcriptional Modulation of the Immune Response by Peroxisome Proliferator-Activated Receptor-{alpha} Agonists in Autoimmune Disease J. Immunol., April 1, 2009; 182(7): 4479 - 4487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zeng, Y. Geng, M. Tretiakova, X. Yu, P. Sicinski, and T. G. Kroll Peroxisome Proliferator-Activated Receptor-{delta} Induces Cell Proliferation by a Cyclin E1-Dependent Mechanism and Is Up-regulated in Thyroid Tumors Cancer Res., August 15, 2008; 68(16): 6578 - 6586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biscetti and R. Pola Endothelial Progenitor Cells and Angiogenesis Join the PPARty Circ. Res., July 3, 2008; 103(1): 7 - 9. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hood, L. Rowen, D. J. Galas, and J. D. Aitchison Systems biology at the Institute for Systems Biology Briefings in Functional Genomics, July 1, 2008; 7(4): 239 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Karpichev, J. M. Durand-Heredia, Y. Luo, and G. M. Small Binding Characteristics and Regulatory Mechanisms of the Transcription Factors Controlling Oleate-responsive Genes in Saccharomyces cerevisiae J. Biol. Chem., April 18, 2008; 283(16): 10264 - 10275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pochetti, C. Godio, N. Mitro, D. Caruso, A. Galmozzi, S. Scurati, F. Loiodice, G. Fracchiolla, P. Tortorella, A. Laghezza, et al. Insights into the Mechanism of Partial Agonism: CRYSTAL STRUCTURES OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma} LIGAND-BINDING DOMAIN IN THE COMPLEX WITH TWO ENANTIOMERIC LIGANDS J. Biol. Chem., June 8, 2007; 282(23): 17314 - 17324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yessoufou, A. Hichami, P. Besnard, K. Moutairou, and N. A. Khan Peroxisome Proliferator-Activated Receptor {alpha} Deficiency Increases the Risk of Maternal Abortion and Neonatal Mortality in Murine Pregnancy with or without Diabetes Mellitus: Modulation of T Cell Differentiation Endocrinology, September 1, 2006; 147(9): 4410 - 4418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kim, K. S. Lee, H. S. Park, S. J. Park, K. H. Min, S. M. Jin, and Y. C. Lee Involvement of IL-10 in Peroxisome Proliferator-Activated Receptor {gamma}-Mediated Anti-Inflammatory Response in Asthma Mol. Pharmacol., December 1, 2005; 68(6): 1568 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Hostetler, A. D. Petrescu, A. B. Kier, and F. Schroeder Peroxisome Proliferator-activated Receptor {alpha} Interacts with High Affinity and Is Conformationally Responsive to Endogenous Ligands J. Biol. Chem., May 13, 2005; 280(19): 18667 - 18682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Li and C. K. Glass PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis J. Lipid Res., December 1, 2004; 45(12): 2161 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ostberg, S. Svensson, G. Selen, J. Uppenberg, M. Thor, M. Sundbom, M. Sydow-Backman, A.-L. Gustavsson, and L. Jendeberg A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects J. Biol. Chem., September 24, 2004; 279(39): 41124 - 41130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Lovett-Racke, R. Z. Hussain, S. Northrop, J. Choy, A. Rocchini, L. Matthes, J. A. Chavis, A. Diab, P. D. Drew, and M. K. Racke Peroxisome Proliferator-Activated Receptor {alpha} Agonists as Therapy for Autoimmune Disease J. Immunol., May 1, 2004; 172(9): 5790 - 5798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Varley, J. Stahlschmidt, B. Smith, M. Stower, and J. Southgate Activation of Peroxisome Proliferator-Activated Receptor-{gamma} Reverses Squamous Metaplasia and Induces Transitional Differentiation in Normal Human Urothelial Cells Am. J. Pathol., May 1, 2004; 164(5): 1789 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Cattley Peroxisome Proliferators and Receptor-Mediated Hepatic Carcinogenesis Toxicol Pathol, February 1, 2004; 32(2_suppl): 6 - 11. [Abstract] [PDF]
|
|
|
|
 |
|
 B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Francis, J.-S. Annicotte, and J. Auwerx PPAR-{alpha} effects on the heart and other vascular tissues Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H1 - H9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Sumanasekera, E. S. Tien, R. Turpey, J. P. Vanden Heuvel, and G. H. Perdew Evidence That Peroxisome Proliferator-activated Receptor alpha Is Complexed with the 90-kDa Heat Shock Protein and the Hepatitis Virus B X-associated Protein 2 J. Biol. Chem., February 7, 2003; 278(7): 4467 - 4473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cunard, D. DiCampli, D. C. Archer, J. L. Stevenson, M. Ricote, C. K. Glass, and C. J. Kelly WY14,643, a PPAR{alpha} Ligand, Has Profound Effects on Immune Responses In Vivo J. Immunol., December 15, 2002; 169(12): 6806 - 6812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Martinez, C. A. Afshari, P. R. Bushel, A. Masuda, T. Takahashi, and N. J. Walker Differential Toxicogenomic Responses to 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Malignant and Nonmalignant Human Airway Epithelial Cells Toxicol. Sci., October 1, 2002; 69(2): 409 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Roberts Evidence for Cross Talk between PPAR{alpha} and p38 MAP Kinase Toxicol. Sci., August 1, 2002; 68(2): 270 - 274. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kiss, R. Ortiz-Aguayo, R. Sharp, G. Merlino, S. S. Thorgeirsson, F. J. Gonzalez, and J. M. Peters Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation Carcinogenesis, June 1, 2001; 22(6): 975 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kaplanski, C. J. Pauley, T. G. Griffiths, T. T. Kawabata, and B. J. Ledwith Differentiation of Rat Oval Cells after Activation of Peroxisome Proliferator-activated Receptor {{alpha}}43 Cancer Res., February 1, 2000; 60(3): 580 - 587. [Abstract] [Full Text]
|
|
|
|
|
|
N.J. Woodyatt, K.G. Lambe, K.A. Myers, J.D. Tugwood, and R.A. Roberts The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs Carcinogenesis, March 1, 1999; 20(3): 369 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nilsson, C. Banfi, U. Diczfalusy, E. Tremoli, A. Hamsten, and P. Eriksson Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Eriksson, L. Nilsson, F. Karpe, and A. Hamsten Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okuno, K. Kajiwara, S. Imai, T. Kobayashi, N. Honma, T. Maki, K. Suruga, T. Goda, S. Takase, Y. Muto, et al. Perilla Oil Prevents the Excessive Growth of Visceral Adipose Tissue in Rats by Down-Regulating Adipocyte Differentiation J. Nutr., September 1, 1997; 127(9): 1752 - 1757. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Ashby, A. Brady, C.R. Elcombe, B.M. Elliott, J. Ishmael, J. Odum, J.D. Tugwood, S. Kettle, and I.F.H. Purchase Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis Human and Experimental Toxicology, January 1, 1994; 13(2_suppl): S1 - S117. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
